Nostalgia has become one of the most powerful currencies in Bollywood’s contemporary marketing apparatus. The recycling of ...

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals (RXRX) added ~11% in the morning trading on Wednesday after J.P. Morgan upgraded the AI-driven biotech to Overweight from Neutral, citing a blockbuster sales potential for ...

Recursion Pharmaceuticals Inc has faced significant challenges in its financial performance, highlighted by a sharp decline in revenue growth, which fell to -32.98% in Q3 2025 from +30.14% in Q2 2025.

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Avatar: Fire and Ash ...

Three recent graduates from the MSU photo program noticed a glaring gap in the photo-journal world. While there has been coverage of climate change and its effects, there was no publication devoted to ...

When Logan Kilpatrick says 2026 will be a “huge year for embodied AI,” it doesn’t sound wildly over-optimistic of a guy who doesn’t know what he’s talking about. To me it looks like a weather report ...